MiNK Therapeutics, Inc. (NASDAQ:INKT) Short Interest Update

MiNK Therapeutics, Inc. (NASDAQ:INKT) was the recipient of a large drop in short interest in the month of October. As of October 31st, there was short interest totalling 51,700 shares, a drop of 20.8% from the October 15th total of 65,300 shares. Approximately 0.5% of the company’s shares are short sold. Based on an average daily volume of 35,500 shares, the short-interest ratio is currently 1.5 days.

Institutional Trading of MiNK Therapeutics

An institutional investor recently raised its position in MiNK Therapeutics stock. Renaissance Technologies LLC boosted its stake in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 21.5% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 127,841 shares of the company’s stock after purchasing an additional 22,613 shares during the quarter. Renaissance Technologies LLC owned about 0.37% of MiNK Therapeutics worth $121,000 at the end of the most recent quarter. Institutional investors own 2.87% of the company’s stock.

MiNK Therapeutics Price Performance

INKT traded up $0.00 during trading on Friday, reaching $0.75. 13,346 shares of the stock traded hands, compared to its average volume of 89,742. MiNK Therapeutics has a fifty-two week low of $0.57 and a fifty-two week high of $1.90. The stock’s 50-day simple moving average is $0.73 and its two-hundred day simple moving average is $0.85. The stock has a market cap of $29.81 million, a price-to-earnings ratio of -1.53 and a beta of 0.05.

MiNK Therapeutics (NASDAQ:INKT) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.03. Research analysts anticipate that MiNK Therapeutics will post -0.33 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $9.00 target price on shares of MiNK Therapeutics in a research note on Friday. Robert W. Baird lowered their price objective on shares of MiNK Therapeutics from $8.00 to $4.00 and set an “outperform” rating on the stock in a research report on Friday.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.